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doi:10.1016/j.nutres.2drogenism and chronic anovulation. Around 60% of PCOS patients are obese. Weight loss has
consistently been shown to improve the clinical status of women with PCOS. We hypothesized that
dietary factors are associated with the hormonal and metabolic abnormalities of PCOS. This case-
control study included 43 women with PCOS and 37 ovulatory, nonhirsute controls matched to the
study group by body mass index. Age ranged from 14 to 38 years. Both groups underwent
anthropometric, laboratory, and nutritional assessment. End points included diet composition, body
fat, and hormonal and metabolic variables related to insulin resistance. The groups had similar
intake of energy, carbohydrate (53.51% ± 8.36% vs 51.83% ± 10.06%), protein (15% [12-18] vs
16% [13-19]), and total fat (30.51% ± 7.90% vs 30.80% ± 7.97%). Total body fat, sum of trunk
skinfold measurements, and waist circumference were higher in the PCOS group (P b .05). Sex
hormone–binding globulin was lower in PCOS patients than in controls, whereas total testosterone,
free androgen index, postprandial glucose, fasting and postprandial insulin, homeostatic model
assessment index, triglycerides, and total and low-density lipoprotein cholesterol (P b .050) were
higher. Homeostatic model assessment index was correlated with central obesity in PCOS patients
and controls alike. No association was detected between androgen status and macronutrient intake.
In conclusion, central obesity and insulin resistance were not strictly associated with energy intake
or dietary macronutrient composition in women with PCOS.
© 2011 Elsevier Inc.Open access under the Elsevier OA license.Keywords: Food intake; Central obesity; Insulin resistance; Nutritional sciences; Sex steroid hormones; Women
Abbreviations: BMI, body mass index; BP, blood pressure; CV, coefficients of variation; FAI, free androgen index; HDL, high-
density lipoprotein; HOMA, homeostasis model assessment; LDL, low-density lipoprotein; PCOS, polycystic
ovary syndrome; SD, standard deviation; SHBG, sex hormone–binding globulin; TT, total testosterone.1. Introduction
Polycystic ovary syndrome (PCOS) is a common
endocrine disorder, affecting 5% to 10% of women of
reproductive age. It is a major cause of anovulatoryauthor. Division of Endocrinology, Hospital de
gre, Rua Ramiro Barcelos, 2350, CEP 90035-003,
zil. Tel.: +55 51 3359 8027; fax: +55 51 3359 8777,
ritzer@ufrgs.br (P.M. Spritzer).
sevier Inc.
011.01.009
Open access under the Elsevier OA license.infertility, irregular menstrual cycles, and hirsutism [1-6].
Obesity is present in 30% to 75% of women with PCOS.
Abdominal obesity is found in most of these women in
association with metabolic disturbances [3-5,7,8], whereas
insulin resistance may occur independently of body mass
index (BMI), with an adverse impact on lipid profile and
blood pressure (BP) [8-11].
A genetic basis has been proposed for PCOS because the
prevalence of this disease is higher among family members
[12,13]. However, the heterogeneous clinical presentation of
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adiposity, overweight, and obesity, is indicative of a
complex interaction between genetic and environmental
factors [7]. In this sense, differences in dietary intake
between women with PCOS and healthy controls have been
described [14], as well as a tendency to overeat, particularly
sweet or starchy foods [15].
In Brazil, the highest rates of obesity and overweight in
women (14.4% and 42.4%, respectively) occur in the South
[16]; but few data are available concerning the implications
of lifestyle and dietary pattern on the prevalence of obesity
and insulin resistance in PCOS [9,14,17,18]. In addition,
despite the substantial evidence supporting an effect of
underweight and excess weight on fertility [17], little is
known about the influence of dietary quality on metabolic
and endocrine control in PCOS [19]. Nevertheless, weight
loss has consistently been shown to improve the clinical
status of PCOS women [18,20].
Taking all these into consideration, we hypothesized that
dietary intake is associated with insulin resistance, lipid
profile, and hormone abnormalities in a sample of women
with PCOS from the South of Brazil. To test this hypothesis,
we designed a case-control study to assess dietary compo-
sition, body fat, and hormonal and metabolic variables
related to insulin resistance in patients with PCOS and in a
group of ovulatory, nonhirsute, BMI-matched women.
Understanding the interaction between dietary factors and
PCOS could provide useful insights for the management of
obesity and metabolic abnormalities in affected women.2. Methods and materials
2.1. Subjects
This case-control study was carried out with patients from
the Gynecological Endocrinology Unit at Hospital de
Clínicas de Porto Alegre, Brazil. Forty-three hirsute
women of reproductive age presenting oligo/amenorrheic
cycles (≤9 cycles per year), increased serum testosterone
levels and/or free androgen index (FAI), and absence of
other disorders causing hirsutism [7,21] were included in the
PCOS group. Thirty-seven BMI- and race-matched non-
hirsute women with regular and ovulatory cycles (luteal
phase progesterone levels N3.8 ng/mL) were recruited to
participate in the study as a control group. None of the
women from either group had received any drugs known to
interfere with hormone levels for at least 3 months before the
study. Women with a BMI higher than 40 kg/m2 or type 2
diabetes were excluded. The study protocol was approved by
the local Ethics Committee (Institutional Review Board
equivalent), and written informed consent was obtained from
all subjects.
2.2. Study protocol
Anthropometric measurements were performed in dupli-
cate and included body weight, height, BMI (current weightin kilograms divided by square meters), waist circumference
(measured at the midpoint between the lower rib margin and
the iliac crest, perpendicularly to the long axis of the body,
with the subject standing balanced on both feet, spread
approximately 20 cm apart, with both arms hanging freely)
[9,22,23], hip circumference (widest circumference over the
buttocks) [24], and waist-to-hip ratio. Obesity was defined as
BMI of at least 30 kg/m2 [25]. Hirsutism was defined as a
modified Ferriman-Gallwey score of 8 or higher [26-28].
Blood pressure was measured after a rest period of 10
minutes, with the subject in the supine position [29].
Hormonal and metabolic evaluation was performed between
days 2 and 10 of the menstrual cycle or on any day if the
patient was amenorrheic. After a 12-hour overnight fast,
blood samples were drawn from an antecubital vein for
determination of plasma cholesterol, high-density lipopro-
tein (HDL) cholesterol, and triglycerides at baseline, and
glucose and insulin before and 2 hours after the ingestion of a
75-g oral glucose load. Impaired glucose tolerance was
determined by glucose levels between 140 and 200 mg/dL,
as defined by the World Health Organization [30]. Blood
samples were also drawn for measurement of sex hormone–
binding globulin (SHBG) and total testosterone (TT). All
samples were obtained between 8:00 AM and 10:00 AM. Free
androgen index was estimated by dividing TT (in nanomoles
per liter) by SHBG (in nanomoles per liter) and multiplying
by 100. Homeostasis model assessment (HOMA) index was
calculated by multiplying insulin (in micro–international
units per milliliter) by glucose (in millimoles per liter) and
dividing this product by 22.5 [31]. The cutoff point to define
insulin resistance was arbitrarily defined as a HOMA index
of at least 3.8 [23].2.3. Biochemical and hormonal assays
Total cholesterol, HDL-cholesterol, triglycerides, and
glucose were determined by colorimetric-enzymatic methods
using the Bayer 1650 Advia System (Mannheim, Germany).
Non–HDL-cholesterol levels were calculated by subtracting
HDL-cholesterol from total cholesterol values. Low-density
lipoprotein (LDL) cholesterol was estimated indirectly using
the following formula: LDL = total cholesterol − HDL −
triglycerides/5. Hormonal measurements were performed
using commercially available kits, as previously described
[23,32,33]. Serum luteinizing hormone (LH) was measured
by a specific immunometric assay (Diagnostic Products
Corporation–DPC, Los Angeles, CA) with sensitivity of
0.05mIU/mL and intra- and interassay coefficients of variation
(CVs) of 3.6%and 6.7%, respectively. Total testosterone levels
were measured by radioimmunoassay (ICN, Costa Mesa, CA)
with an intra- and interassay CVs of 10% and 11.6%,
respectively. Sex hormone–binding globulin was measured
by chemiluminescent enzyme immunoassay (DPC) with a
sensitivity of 0.2 nmol/L and intra- and interassayCVs of 6.1%
and 8.0%, respectively. Serum insulin levels were measured
with an electrochemiluminescence immunoassay (Roche
Table 1
Clinical and anthropometric features of patients with PCOS and nonhirsute
ovulatory controls
Variable PCOS (n = 43) Controls (n = 37) P
Weight (kg) 79.64 ± 15.04 77.03 ± 13.95 .420
BMI (kg/m²) 30.92 ± 5.48 29.66 ± 5.16 .290
Systolic BP (mm Hg) 121.45 ± 15.81 116.32 ± 9.56 .080
Diastolic BP (mm Hg) 77.56 ± 11.7 74.03 ± 10.18 .171
Skinfold thickness total
body fat (%)
30.71 ± 6.67 26.8 ± 5.85 .007
Sum of trunk skinfolds (mm) 127.92 ± 36.51 104.34 ± 29.95 .002
Waist circumference (cm) 90.83 ± 11.33 85.48 ± 9.94 .029
Waist-to-hip ratio 0.82 ± 0.07 0.77 ± 0.05 .001
Values are expressed as mean ± SD (Student t test).
99M.K. Toscani et al. / Nutrition Research 31 (2011) 97–103Diagnostics GmbH, D-68298 Mannheim, Germany) with a
sensitivity of 0.20 mIU/mL and intra- and interassay CVs of
1.8% and 2.5%, respectively.
2.4. Measurement of skinfold thicknesses
Skinfold thickness was estimated using a caliper (Cescorf,
Mitutoyo, Porto Alegre, Brazil) with 0.1-mm scale and a jaw
pressure of 10 g/mm2. Measurements were obtained at the
triceps and subscapular, abdominal, and suprailiac regions.
Percentage body fat was calculated using the Faulkner
(1968) formula: percentage total body fat = (triceps +
subscapular + suprailiac + abdominal skinfolds × 0.153) +
5.783. The sum of 3 skinfold measurements (subscapular,
suprailiac, and abdominal, referred to as the sum of trunk
skinfolds and expressed in millimeters) was used to estimate
truncal adiposity, as previously reported [23].
2.5. Nutritional assessment
To determine the amount and quality of all foods and
beverages consumed the day before, a validated 24-hour
dietary recall based on individual interviews was used
[34-36]. Each participant answered the questionnaire
specifying details about the brand, size, and volume of
each portion consumed based on food replicas, drawings
and photographs, and home utensils (such as glasses, cups,
mugs, and spoons) displayed during the interview.
To estimate macronutrient intake and the reliability of
our 24-hour dietary recall interviews, urea and creatinine
were determined in 24-hour urine samples. Agreement was
assessed by estimating protein intake according to the
dietary recall and comparing this estimate to urea and
creatinine measurements [37]. Protein balance was deter-
mined on the basis of 24-hour urinary urea using the
following formula: protein intake (grams of protein per
day) = nitrogen intake × 6.25, where nitrogen intake =
urinary urea nitrogen (urinary urea/2) + nonurea nitrogen
(losses through skin, hair, nails, and others = 0.031 g/kg
current weight). This calculation took into account the
excretion in the urine of most of the amino acid–derived
nitrogen produced by protein catabolism [38].
2.6. Statistical analyses
Results are presented as means ± standard deviation (SD),
except in the case of nonparametric data, which are presented
as medians and interquartile range. Two-tailed Student t tests
were used to compare the differences between means of
parametric continuous variables. The Mann-Whitney U test
was used for comparisons of nonparametric data. Statistical
significance for categorical variables was calculated by
Pearson χ2 test. Spearman rank correlation coefficient was
calculated between variables using a 2-tailed significance
test for variables with non-Gaussian distribution. Sample
size calculation was based on a previous clinical trial
(Clinical Trial Registration Number: NCT01184963) carried
out by our group. In that project, the primary outcome wasweight loss in PCOS patients and controls following
specific diets. In all cases, statistical analysis was performed
using the Statistical Package for the Social Sciences 16
(SPSS Inc, Chicago, IL). Data were considered to be
significant at P b .05.3. Results
Twenty-eight (90%) of 31 PCOS patients and 26 (74%) of
35 controls were white. The remaining participants were of
mixed African and European descent. Mean age in the PCOS
group was 22.67 ± 5.55 years vs 29.70 ± 4.93 years for
controls (P = .001). Participants in both groups were
predominantly obese (57% and 50% for PCOS and controls,
respectively), whereas 25% and 31% of participants in the
PCOS and control groups were overweight, respectively.
Normal weight was observed in 18% and 19% of participants
in the PCOS and control groups, respectively.
Table 1 summarizes the clinical and anthropometric
profile of each group. Body mass index was similar in both
groups. The PCOS patients had higher percentage body fat
(P = .007) and sum of trunk skinfolds (P = .002), and
increased waist circumference (P = .029) and waist-to-hip
ratio (P = .001) as compared with controls.
Table 2 shows the hormonal and metabolic profile of
the PCOS and control groups. The PCOS patients had
significantly lower SHBG levels and higher TT, FAI,
postload glucose, fasting and postload insulin, HOMA
index, triglycerides, total cholesterol, and LDL-cholesterol
compared with control women. No between-group differ-
ences in fasting glucose or HDL-cholesterol were observed.
Twenty-two (53%) of 43 PCOS patients and only 2 (5.5%,
P b .05) of 36 controls had insulin resistance (HOMA N3.8).
Regarding food intake (Table 3), there were no statistical
differences in energy, carbohydrate, protein, and lipid intake
between groups. Patients with PCOS had a slightly lower
protein intake than the control group (P = .05). Macronu-
trient intake was in accordance with National Institutes
of Health recommendations [39], although both soluble
(5-10 g/d) and insoluble (15-20 g/d) fiber intakes were lower
than recommended [40].
Table 2
Hormonal and metabolic features of patients with PCOS and nonhirsute ovulatory controls
Variable PCOS (n = 43) Controls (n = 37) P value
TT (ng/mL)a 1.10 (0.90-1.40) 0.32 (0.21-0.39) .001
SHBG (nmol/L)a 28.50 (14.80-50.60) 44.60 (29.55-56.04) .030
Free androgen indexa 19.90 (9.93-29.96) 2.76 (1.70-4.70) .001
Fasting glucose (mg/dL) 88.69 ± 8.92 88.89 ± 7.08 .910
Glucose 129′ (mg/dL) 118.15 ± 28.72 96.43 ± 18.24 .001
Fasting insulin (μIU/mL)a 17.75 (10.95-33.60) 10.57 (5.97-13.73) .001
Insulin 129′ (μIU/mL)a 126.90 (56.45-190.60) 49.86 (27.70-85.48) .001
HOMA indexa 3.85 (2.30-7) 2.13 (1.30-3.16) .001
Triglycerides (mg/dL)a 86 (60-1420) 63 (48.50-97.50) .043
Total cholesterol (mg/dL) 170 ± 47.84 162.91 ± 35.05 .019
HDL-cholesterol (mg/dL) 51.34 ± 10.19 52.02 ± 12.83 .790
LDL-cholesterol (mg/dL) 155.56 ± 42.92 136.42 ± 33.41 .031
Values represent means ± SD or amedian and interquartile range (25% to 75%). Statistical comparisons were performed by Student t test for means and by
Mann-Whitney U test for amedians.
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range [39]: carbohydrate, roughly 50% to 55%; protein,
15%; and total fat, around 30% of total energy intake
(Table 4). Intake of cholesterol (b300 mg/d) and saturated
fatty acids (8%-10%) was also within the reference range.
Intake of monounsaturated fatty acids (N15%) and of
polyunsaturated fatty acids (N10%) was slightly below
recommended levels [39].
Homeostasis model assessment was positively associated
with BMI (r = 0.680, P = .0001 in PCOS and r = 0.645, P =
.0001 in controls), percentage body fat (r = 0.709, P = .0001
in PCOS and r = 0.623, P = .0001 in controls), and sum of
trunk skinfolds (r = 0.715, P = .0001 in PCOS and r = 0.635,
P = .0001 in controls). These associations remained
significant after adjustment for FAI. No correlations between
total energy intake and androgen status were observed.4. Discussion
Few studies so far have addressed the interaction
between dietary quality and endocrine abnormalities inTable 3
Macronutrient intake in patients with PCOS and nonhirsute ovulatory controls
Variable PCOS (n = 43)
Energy intake (kJ)a 7135 (5409-9748)
Protein (g/d) 69.22 ± 30.7
Vegetable protein (g/d)a 17.31 (13.50-25.12)
Saturated fatty acid (g/d)a 18.42 (12.79-24.42)
% Saturated fatty acid 8.87 ± 2.84
Monounsaturated fatty acid (g/d)a 17.99 (12.02-24.71)
% Monounsaturated fatty acid 9.44 ± 3.04
Polyunsaturated fatty acids (g/d)a 13.29 (7.56-19.08)
% Polyunsaturated fatty acidsa 6.53 (3.89-8.69)
Cholesterol (mg/d)a 150 (105.9-257.6)
Total fiber (g/d)a 11.62 (7.18-15.49)
Soluble fiber (g/d)a 3.99 (2.09-4.86)
Insoluble fiber (g/d)a 7.17 (4.95-11.51)
Values represent means ± SD or amedian and interquartile range (25% to 75%). Stat
Whitney U test for amedians.PCOS [41-43]. In the present study, no differences were
observed between southern Brazilian women with PCOS
and controls in terms of energy or macronutrient intake.
This finding contradicts our initial hypothesis that dietary
intake would be associated with insulin resistance, lipid
profile, and hormone abnormalities in PCOS. Although the
high prevalence of obese women in both groups might have
resulted in a lower discriminative effect, which would
preclude detection of differences, previous studies [14]
have reported similar results in US PCOS patients and
controls with BMI values similar to those of our subjects.
In addition, a study comparing Italian and US women
with PCOS found no statistical differences in energy and
nutrient intake between the 2 groups, whereas saturated fat
intake was almost twice as high in US as compared with
Italian women [44]. However, the fact that US participants
had higher BMIs than those in the Italian group may have
affected this result.
Some investigators have suggested that women with
PCOS have a tendency to overeat, either for emotional [45]
or for biological reasons. Holte et al [46] postulated thatControls (n = 37) P value
8368 (5921-10039) .50
80.77 ± 32.62 .05
18.68 (13.59-24.69) .54
21.58 (12.37-26.91) .43
9.71 ± 3.46 .23
18.17 (11.84-26.02) .92
9.01 ± 3.51 .56
12.98 (9.1-21.28) .56
6.69 (4.97-10.54) .49
202.6 (122.94-314.93) .09
11.02 (6.44-18.45) .825
3.57 (1.72-4.97) .790
7.56 (4.41-11.74) .965
istical comparisons were performed by Student t test for means and by Mann-
Table 4
Macronutrient distribution in patients with PCOS and nonhirsute ovulatory
controls
Variable PCOS (n = 43) Controls (n = 37) P value
Carbohydrate (%) 53.51 ± 8.36 51.83 ± 10.06 .41
Protein (%) 17.12 ± 10.08 16.78 ± 4.15 .84
Total fat (%) 30.51 ± 7.90 30.80 ± 7.97 .88
Values represent means ± SD. Statistical comparisons were performed by
Student t test for means.
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glycemia. These hypoglycemic episodes could cause
carbohydrate cravings and decreased postprandial satiety,
leading to overeating and obesity. Other studies on
disordered metabolism and PCOS have produced contradic-
tory findings [47,48]. Robinson et al [48] found that obese
and lean women with PCOS exhibited reduced postprandial
thermogenesis (a measure of metabolic efficiency) compared
with obese and lean women without PCOS; the reduction in
postprandial thermogenesis in women with PCOS was
correlated with reduced insulin sensitivity. In contrast,
other studies [49] found no difference in resting metabolic
rate or postprandial thermogenesis between obese women
with and without PCOS.
The present study shows that, despite being younger
than controls, participants with PCOS had more central
obesity as measured by the sum of trunk skinfolds,
waist circumference, and waist-to-hip ratio. Central
obesity, defined as increased abdominal fat, is a marker of
insulin resistance and a risk factor for cardiovascular disease
[50,51]. In fact, PCOS patients have been considered a high-
risk subgroup for diabetes and cardiovascular disease. In our
study, women with PCOS also had lower SHBG and higher
androgen levels and a more adverse metabolic profile than
the control group, confirming previous observations made
by our group [6,23] and by others [52,53]. In PCOS
patients, the compensatory hyperinsulinemia that follows
insulin resistance leads to both an increase in ovarian
androgen secretion and a reduction in SHBG levels. Hence,
obese women with PCOS are frequently more hyperandro-
genic that nonobese ones [54-57].
A complex interrelationship between different nutritional
factors and endocrine status is recognized. The quality of diet
seems to play a role in the regulation of sex steroid
metabolism. In this sense, it is reasonable to presume that a
low-fiber, high-lipid diet may increase circulating estrogen
and androgen concentrations [58], whereas a very lipid-rich
diet may decrease SHBG concentrations, with a consequent
increase in both androgen and estrogen availability to target
tissues [41]. In the present study, HOMA index was
correlated with markers of central obesity such as waist
circumference and sum of trunk skinfolds in both the PCOS
and control groups; but no associations were found between
androgen status and macronutrient intake.
One limitation of the present study is the high prevalence
of overweight and obesity among both PCOS and controlgroups. This precludes extrapolation of our findings to
populations of lean women with PCOS (BMI b25), although
insulin resistance and central adiposity are also frequent
in those women compared with healthy women with the
same BMI.
In conclusion, PCOS patients did not differ from controls
in terms of the amount and quality of dietary macronutrient
intake. Women with PCOS, however, had greater waist
circumference and HOMA index, as well as a more adverse
lipid profile, than the control group. This suggests that
insulin resistance is not strictly associated with energy intake
or dietary composition in PCOS.
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